EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

Novo Nordisk filed semaglutide for approval with the FDA and EMA in December. The drug suppresses appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating.

The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction ...

Health Canada has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of non-fatal heart attack ... Lake noted in the clinical trial of Wegovy to prevent cardiovascular disease ...

Health Canada has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of non-fatal heart attack, the drug maker says. Novo Nordisk said Wednesday that Wegovy is the first Health ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on ...

At a testy hearing in Manhattan on Tuesday, NBC News reported, U.S. District Judge Lewis Liman said Giuliani’s “social calendar” was not an adequate reason to postpone the Jan. 16 trial ...

Nov 27 (Reuters) - Canada's health regulator has approved Novo Nordisk's (NOVOb.CO), opens new tab weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in ...

(Reuters) - Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said ...

picture alliance / Contributor / Getty Images Eli Lilly and Novo Nordisk shares rose Tuesday ... that it can cause ailments like diabetes and heart disease, which are covered under the rules.